Kodiak Sciences Inc (KOD)

Business: Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.

IPO Date: 04-Oct-2018

Co-Founder, Chairman, CEO & Pres: Dr. Victor Perlroth M.D.

Sr. VP, CFO & Sec.: Mr. John A. Borgeson CPA, M.B.A., MBA, CPA

Listing: NASDAQ: KOD

Country: United States

Headquarters: Palo Alto, CA

Website: https://kodiak.com

Market cap: $402.64 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-312.25 Mln

Cash: $671.73 Mln

Total Debt: $81.40 Mln

Insider's Holding: 7.91%

Liquidity: Low

52 Week range: $4.90 - 131.97

Shares outstanding: 51,953,600

6 Years Aggregate:

• CFO: $-367.58 Mln
• EBITDA: $-507.29 Mln
• Net Profit: $-533.96 Mln